Losartan Did Not Significantly Lower Hepatic Inflammation in Children With NAFLD
Losartan, an angiotensin II receptor blocker, does not significantly affect the amount of hepatic inflammation and injury in children with nonalcoholic fatty liver disease (NAFLD), according to a study published in the August 2022 edition of Hepatology. Losartan has been proposed as a treatment for the disease. The Nonalcoholic Steatohepatitis Clinical Research Network conducted the […]
Read More